C
Chi-yuan Hsu
Researcher at University of California, San Francisco
Publications - 291
Citations - 34394
Chi-yuan Hsu is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 63, co-authored 264 publications receiving 29695 citations. Previous affiliations of Chi-yuan Hsu include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
TL;DR: The longitudinal glomerular filtration rate was estimated among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured between 1996 and 2000 and who had not undergone dialysis or kidney transplantation.
Journal ArticleDOI
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
TL;DR: In this paper, the longitudinal glomerular filtration rate (GFR) among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured between 1996 and 2000 and who had not undergone dialysis or kidney transplantation.
Journal ArticleDOI
Body Mass Index and Risk for End-Stage Renal Disease
TL;DR: In this study of a cohort of patients in a large integrated health care system, people with higher body mass index (BMI) at baseline had a higher incidence of end-stage renal disease (ESRD) even af...
Journal ArticleDOI
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Tamara Isakova,Patricia Wahl,Gabriela Vargas,Orlando M. Gutiérrez,Julia J. Scialla,Huiliang Xie,Dina Appleby,Lisa Nessel,Keith Bellovich,Jing Chen,L. Lee Hamm,Crystal A. Gadegbeku,Edward Horwitz,Raymond R. Townsend,Cheryl A.M. Anderson,James P. Lash,Chi-yuan Hsu,Mary B. Leonard,Myles Wolf +18 more
TL;DR: Increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH, and may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels.
Journal ArticleDOI
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease
Tamara Isakova,Huiliang Xie,Wei Yang,Dawei Xie,Amanda H. Anderson,Julia J. Scialla,Patricia Wahl,Orlando M. Gutiérrez,Susan Steigerwalt,Jiang He,Stanley Schwartz,Joan Lo,Akinlolu O. Ojo,James H. Sondheimer,Chi-yuan Hsu,James P. Lash,Mary B. Leonard,John W. Kusek,Harold I. Feldman,Myles Wolf +19 more
TL;DR: Elevated FGF-23 is an independent risk factor for end-stage renal disease in patients with relatively preserved kidney function and for mortality across the spectrum of chronic kidney disease.